Arbutus reports second quarter 2023 financial results and corporate update

Regulatory approval received in new zealand to advance ab-101, our oral pd-l1 inhibitor, into a phase 1 clinical trial with dosing to begin this quarter
ABUS Ratings Summary
ABUS Quant Ranking